Revolution Medicines, Inc. 8-K

What Happened
Revolution Medicines, Inc. (RVMD) announced its financial results for the quarter ended March 31, 2026 on May 6, 2026. The company furnished a press release with the results as Exhibit 99.1 to a Current Report on Form 8-K. The company notes the information is being furnished (not “filed”) under the Securities Exchange Act and is not incorporated by reference into other filings.

Key Details

• Item 2.02 (Results of Operations and Financial Condition) reported on May 6, 2026 for the quarter ended March 31, 2026.
• Press release summarizing the quarterly results is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K was signed by President and CEO Mark A. Goldsmith, M.D., Ph.D.
• The filing includes the Inline XBRL Cover Page Interactive Data File (Exhibit 104).

Why It Matters
This Form 8-K is the company’s official announced quarterly results — investors should review the Exhibit 99.1 press release and any accompanying financial statements for specific metrics (revenue, net income/loss, cash runway, and guidance) and any pipeline or program updates. Note the filing is furnished rather than filed under Section 18, which affects its legal treatment and incorporation by reference into other SEC filings.